Stockscreener 앱 받기
4.75
7.22%
0.32
시간 외 거래:
1.90
-2.85
-60.00%
전일 마감가:
$4.43
열려 있는:
$4.6988
하루 거래량:
18,223
Relative Volume:
0.40
시가총액:
$30.28M
수익:
$500.00K
순이익/손실:
$-9.23M
주가수익비율:
-3.1559
EPS:
-1.5051
순현금흐름:
$-8.47M
1주 성능:
+20.56%
1개월 성능:
+33.05%
6개월 성능:
+23.70%
1년 성능:
-63.18%
1일 변동 폭
$4.498
$4.92
1주일 범위
$3.99
$4.92
52주 변동 폭
$3.1006
$15.91
Exicure Inc Stock (XCUR) Company Profile
명칭
Exicure Inc
전화
847-673-1707
주소
2430 N. HALSTED ST., CHICAGO, IL
Compare XCUR vs MOBBW, PSNYW, GOODO, SHMD, DWLD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| 0.625 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.52 | 3.71B | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.58 | 414.42M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
GOODO
Gladstone Commercial Corporation
|
19.91 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
6.52 | 377.54M | 52.15M | -21.46M | 0 | -0.4675 |
|
DWLD
Davis Select Worldwide ETF
|
43.90 | 0 | 0 | 0 | 0 | 0.00 |
Exicure Inc Stock (XCUR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2020-12-18 | 개시 | BMO Capital Markets | Outperform |
| 2019-11-20 | 개시 | Guggenheim | Buy |
Exicure Inc 주식(XCUR)의 최신 뉴스
Breakout Zone: Does Exicure Inc offer margin of safetyMarket Performance Report & High Conviction Buy Zone Alerts - baoquankhu1.vn
Exicure Inc Stock (ISIN: US30205M1027) Faces Uncertainty Amid Biotech Sector Volatility - AD HOC NEWS
Short Interest in Exicure, Inc. (NASDAQ:XCUR) Rises By 14.3% - Defense World
Pharma News: What is the Moat Score of Exicure IncEarnings Risk Summary & High Accuracy Trade Alerts - baoquankhu1.vn
Aug Catalysts: Is Exicure Inc stock influenced by commodity prices2026 Retail & Daily Profit Maximizing Tips - baoquankhu1.vn
(XCUR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Can Exicure Inc continue delivering strong returnsTrade Entry Report & Daily Growth Stock Investment Tips - baoquankhu1.vn
Breakout Watch: Whats the fair value of Exicure Inc stockTreasury Yields & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Trend Review: Is Exicure Inc stock a hidden gemDay Trade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Activity Recap: Can Exicure Inc continue delivering strong returnsLayoff News & Fast Moving Market Watchlists - baoquankhu1.vn
(XCUR) Risk Channels and Responsive Allocation - Stock Traders Daily
XCUR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
David Giljohann - Crain's Chicago Business
XCUR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Exicure (XCUR) CAO has shares withheld to cover RSU taxes - Stock Titan
Exicure Announces New CEO and Interim CFO Appointments - The Globe and Mail
Bear Alert: Whats the fair value of Exicure Inc stockFed Meeting & AI Driven Price Forecasts - baoquankhu1.vn
Can Exicure Inc. continue delivering strong returnsWeekly Trade Summary & Weekly High Return Opportunities - mfd.ru
Market Pulse: Does Exicure Inc stock have upside surprise potentialJuly 2025 WrapUp & Smart Allocation Stock Reports - baoquankhu1.vn
Exicure announces board and executive changes, CEO and CFO resignations By Investing.com - Investing.com India
Exicure announces board and executive changes, CEO and CFO resignations - Investing.com Nigeria
Exicure Announces Major Leadership and Board Restructuring - TipRanks
Leadership shake-up at Exicure (NASDAQ: XCUR) as CEO, CFO and directors exit - Stock Titan
Why Exicure Inc. stock remains on watchlistsJuly 2025 Trends & Technical Pattern Recognition Alerts - mfd.ru
Can Exicure Inc. stock sustain revenue growth2025 Stock Rankings & Accurate Buy Signal Alerts - mfd.ru
Aug Intraday: What is the Moat Score of Exicure IncTrade Risk Summary & Capital Protection Trading Alerts - baoquankhu1.vn
Exicure announces publication of results from Phase 2 study of burixafor - TipRanks
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Bur - GuruFocus
Exicure (XCUR) Publishes Promising Phase 2 Study Results for Burixafor - GuruFocus
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - The Manila Times
Exicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease Treatment - Quiver Quantitative
Same-day stem cell collection seen in Exicure Phase 2 cancer trial - Stock Titan
Market Catalysts: Can Exicure Inc expand into new marketsJuly 2025 Chart Watch & High Conviction Buy Zone Picks - baoquankhu1.vn
Quarterly Earnings: Should I invest in NEPH before earningsWeekly Market Outlook & Daily Profit Maximizing Tips - baoquankhu1.vn
Jobs Data: Does Exicure Inc offer margin of safetyGap Up & Verified Entry Point Detection - baoquankhu1.vn
Trade Report: What is the Moat Score of Exicure Inc2025 Sector Review & Trade Opportunity Analysis - baoquankhu1.vn
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up - TipRanks
Market Trends: What is the Moat Score of Exicure IncJuly 2025 Update & Long-Term Safe Investment Ideas - baoquankhu1.vn
Exicure completes Phase 2 trial milestone and plans $1 million payment to GPCR Therapeutics - Investing.com UK
Exicure to Pay GPCR Therapeutics $1 Million for First Milestone Completion - 아시아경제
Exicure Achieves Milestone in Burixafor Phase 2 Program - TipRanks
Exicure Achieves First Milestone in Collaboration with GPCR Therapeutics - TradingView
Exicure to present phase 2 burixafor data at 2026 transplantation meeting - Investing.com Nigeria
Major Exicure Stakeholder Makes Bold Move With Large Share Sale - TipRanks
Insider Sell: Hitron Exicure Sells 258,367 Shares of Exicure Inc (XCUR) - GuruFocus
Exicure HiTron sells shares worth $1.16 million By Investing.com - Investing.com Nigeria
Exicure HiTron sells shares worth $1.16 million - Investing.com
Exicure to present data from burixafor Phase 2 trial at 2026 Tandem Meetings - TipRanks
Exicure (XCUR) to Showcase Phase 2 Trial Data on Burixafor at 20 - GuruFocus
Exicure Inc (XCUR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):